Phuturdex › Diseases › Liver cirrhosis
Drugs in development · updated 30 October 2026
Liver cirrhosis: drugs in development
As of 30 October 2026 there are 32 active clinical trials (recruiting or ongoing, phases I–III) on 38 drugs for liver cirrhosis. 9 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Hydronidone | III | 2 | NCT07412236 |
| AZD2389 | II | 1 | NCT07610837 |
| BI 3802876 | II | 1 | NCT07325526 |
| Epigallocatechin gallateEGCG | II | 1 | NCT06015022 |
| Foscenvivint | II | 1 | NCT07681089 |
| NicotinamideNicotinomide | II | 1 | NCT06599918 |
| RTX001 | I–II | 1 | NCT06823713 |
| Secretome | I | 1 | NCT06629909 |
| Siplizumab | I | 1 | NCT06455280 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ApixabanEliquis, Abanta® | III | 3 | NCT07726693 |
| EnoxaparinLovenox, Lovenox (Preservative Free)® | II–III | 2 | NCT06818279 |
| AspirinVazalore®, Durlaza® | III | 1 | NCT07529262 |
| Candesartan | III | 1 | NCT03770936 |
| Dabigatran | II–III | 1 | NCT06818279 |
| OrphenadrineNorflex®, Disipal® | III | 1 | NCT02423395 |
| PraziquantelBiltricide® | II–III | 1 | NCT07754617 |
| RamiprilVostally®, Altace® | III | 1 | NCT03770936 |
| ResmetiromMGL-3196, Rezdiffra® | III | 1 | NCT05500222 |
| SimvastatinFlolipid®, Zocor® | II–III | 1 | NCT04971577 |
| AmbrisentanLetairis®, Ambrisentan Viatris (previously Ambrisentan Mylan)® | II | 1 | NCT06256432 |
| AtorvastatinLipitor, Atorvaliq® | II | 1 | NCT05028829 |
| CarvedilolCoreg Cr®, Coreg® | II | 1 | NCT07350070 |
| DanazolDanocrine® | II | 1 | NCT04873102 |
| DigoxinLanoxin®, Lanoxicaps® | II | 1 | NCT06588699 |
Sorted by most advanced phase and number of active trials. Showing 15 of 29 drugs.
All 38 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Liver Cirrhosis, Biliary 13 drugs
- Pruritus 18 drugs
- Sclerosing cholangitis 17 drugs
- Ascending cholangitis 3 drugs
- Digestive System Diseases 36 drugs
- Cholestasis 6 drugs
- Alcoholic liver cirrhosis 3 drugs
- Atopic dermatitis 91 drugs
- Acute-on-chronic liver failure 7 drugs
- Alcoholic hepatitis 5 drugs
- Liver disease 33 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Liver disease 33 drugs
- Fibrosis 52 drugs
- Glandular and epithelial neoplasm 12 drugs
- Fatty liver disease 23 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008103 “Liver Cirrhosis”.